Envestnet Portfolio Solutions Inc has decreased its stake in
West Pharmaceutical Services, though
Generali Asset Management,
Vanguard Personalized Indexing Management LLC,
TD Asset Management, and
Callan Family Office LLC have all increased theirs.
West Pharmaceutical appointed a new CFO,
Robert McMahon. The company's valuation and
Q3 earnings are under focus with expectations of a 21% upside potential while analyst confidence grows. As
West Pharmaceutical prepares to report
Third-Quarter 2025 results,
West has also declared their
Second-Quarter 2025 results and
Fourth-Quarter 2025 dividend distribution. There's a cautious outlook due to non-core weakness and injectable disruption risks.
Aberdeen Group plc,
Yousif Capital Management and
111 Capital have bought West Pharmaceutical Services' shares.
West Pharmaceutical recently surpassed Q2 earnings and revenue estimates with unexpectedly strong earnings, though the stock dropped after. There's rising demand for bioprocessing equipment, however, concern remains over the stock's underperformance and downfall.
West Pharmaceutical Services WST News Analytics from Thu, 13 Feb 2025 08:00:00 GMT to Sat, 18 Oct 2025 09:16:40 GMT -
Rating -2
- Innovation 5
- Information 6
- Rumor -7
